Pierre Layrolle obtained a Ph.D. in biomaterials from the University of Toulouse in 1994. He then spent 2 years in Tsukuba, Japan as a post-doctoral researcher. For 5 years, he worked as a Senior Research Scientist in the tissue engineering company IsoTis in The Netherlands. In 2003, he joined INSERM as Director of Research in Nantes leading a team on bone tissue engineering. He was the coordinator or partner of several European projects (REBORNE, MAXIBONE, ORTHOUNION, PARAGEN, ORTHO ALLO UNION) to translate innovative bone regenerative therapies into clinical trials. From 2010 to 2020, he started to study bone tumors and led a research team on inflammation and cell communications in bone pathologies. In 2021, he has moved to Inserm, ToNIC lab in Toulouse to develop 3D bioprinting and organs on chips. Pierre Layrolle has authored around 250 peer-reviewed publications (22800 citations, h-index 80) and invented 15 patents.
Prof. Pierre Payoux is a professor of Biophysics and Nuclear Medicine, head of the Nuclear Medicine Department of the University Hospital of Toulouse and of UMR 12 14 INSERM/UPS Toulouse Neuroimaging Centre ToNIC. His research focuses on the development of innovative SPECT and PET radioligands and optimization of molecular imaging quantification techniques. His research interests include dementia, PET, Neuroimaging, molecular imaging, Parkinson, etc.
Dr. Chavanas is a INSERM senior researcher at Toulouse NeuroImaging Center (ToNIC, Toulouse, France). He has deep expertise in disease modeling, neural stem cells and inherited optic neuropathies. In his early works at INSERM, Thomas Jefferson University in Philadelphia and the Wellcome Trust Centre for Human Genetics in Oxford, Dr. Chavanas studied the genetics and pathophysiology of rare inherited skin diseases including Netherton syndrome, for which he discovered and studied the causative gene, SPINK5, and revealed its role in atopic dematitis. Those works paved the way to gene therapy approaches and enabled prenatal testing in numerous families over the past 20 years. At Toulouse Purpan Centre for Pathophysiology, Dr. Chavanas’ group provided key insight on the neuropathogeny of the congenital infection by human cytomegalovirus, the most common cause of brain congenital abnormalities, unraveling candidate severity factors. At ToNIC, Dr. Chavanas now develops innovative
human neural tissues models using stem cells and 3D bioprinting on microelectrode arrays. His group aims to implement an innovative bioprinted neuroretinal Interface for drug screening and athophysiological studies. Dr. Chavanas coordinates the consortium VISION, with clinicians and researchers in psychosociology, neuroimaging, microelectronics and disease modeling, and the patient association for optic neuropathies Ouvrir les Yeux.
